Liliana Vasquez

Liliana Vasquez

Auto-generated profile, based on publicly available information

Liliana Vasquez

Department of Noncommunicable Diseases and Mental Health Pan American Health Organization Washington District of Columbia USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
GGGlobal Retinoblastoma Study Group
Global Retinoblastoma Study Group
IFIdo Didi Fabian
Ido Didi Fabian
EAElhassan Abdallah
Elhassan Abdallah
SAShehu U. Abdullahi
Shehu U. Abdullahi
RARula A. Abdulqader
Rula A. Abdulqader
RBRichard Bowman
Richard Bowman
Retinoblastoma, the most common eye cancer of childhood, is fatal if left untreated. Prognosis of patients with retinoblastoma in high-income countries (HICs) has improved over the past 50 years, now reaching a near 100% disease-free survival rate.1-3 This is attributed to several factors, including (1) creation of specialized referral centers, (2) decoding of the genetic basis of the disease, (3) formation of screening programs, and (4) the introduction of chemotherapy.4 In HICs, retinoblastoma is a curable disease, and attention has now shifted to eye salvage5,6 and improvement of quality of life.7 In low- and middle-income countries (LMICs), where more than 80% of global retinoblastoma cases arise, the prognosis is poor, and it is assumed that this is because of delayed diagnosis and treatment.8-10 Publications from LMICs are scarce, and many countries do not report their retinoblastoma data.11 The stage of retinoblastoma at the time of diagnosis in low-income, middle-income, and high-income countries has not been surveyed globally. This information is important for policy and health care planning at national and international levels.

1 June 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
LVLiliana Vasquez
Liliana Vasquez
CSClaudia Sampor
Claudia Sampor
GVGabriela Villanueva
Gabriela Villanueva
EMEssy Maradiegue
Essy Maradiegue
MGMercedes Garcia-Lombardi
Mercedes Garcia-Lombardi
GCGuillermo L Chantada
Guillermo L Chantada

1 October 2017 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
LVLiliana Vasquez
Liliana Vasquez
ELEsmeralda León
Esmeralda León
BBBrady Beltran
Brady Beltran
IMIvan Maza
Ivan Maza
MOMonica Oscanoa
Monica Oscanoa
JGJenny Geronimo
Jenny Geronimo
Background: Pretreatment neutrophil-to-lymphocyte ratio (NLR) and absolute lymphocyte count (ALC) recovery have been shown to be associated with prognosis in several types of cancer in adults. However, evidence in pediatric cancer is scarce. The aim of our study was to evaluate whether pretreatment NLR and lymphocyte recovery are prognostic factors in pediatric sarcomas. Materials and Methods: Study participants were identified from a retrospective cohort of 100 children with osteosarcoma (n=55), rhabdomyosarcoma (n=22), and Ewing sarcoma (n=23). Data for the hematological variables were obtained from medical records and analyzed with other known prognostic factors in univariate and multivariate analyses. Results: In multivariate analysis, NLR>2 was an independent prognostic factor for OS in patients with osteosarcoma (hazard ratio [HR], 2.27, 95% confidence interval [CI], 1.07-5.30; P=0.046) along with metastatic disease and poor histologic response; as well as in patients with rhabdomyosarcoma (HR, 4.76, 95% CI, 1.01-22.24; P=0.0237) along with metastatic disease and risk group. ALC recovery correlated for inferior OS in osteosarcoma (HR, 3.34, 95% CI, 1.37-8.12; P=0.008) and rhabdomyosarcoma (HR, 3.89; 95% CI, 1.01-14.89; P=0.0338). Conclusions: Our study confirms that NLR and ALC recovery are independent prognostic factors for pediatric sarcomas, implying an important role of immune system in survival. Clinical utility of these prognostic biomarkers should be validated in larger pediatric studies.

2 February 2016 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LVLiliana Vasquez
Liliana Vasquez
FTFanny Tarrillo
Fanny Tarrillo
MOMonica Oscanoa
Monica Oscanoa
IMIvan Maza
Ivan Maza
JGJenny Geronimo
Jenny Geronimo
LSLuis Sialer
Luis Sialer
Background: The aim of this retrospective study was to define clinical and pathologic features and prognostic factors among children and adolescents diagnosed with high-grade osteosarcoma of the extremities. Methods: A total of 73 patients younger than 18 years old diagnosed with primary osteosarcoma of the extremities between January 1998 and December 2013 were retrospectively evaluated. Prognostic factors such as age, gender, primary tumor site, alkaline phosphatase and lactate dehydrogenase levels, metastatic disease, pathological fracture, histological response and surgery type were analyzed to evaluate their effects on overall (OS) and event free survival (EFS). Results: At a median follow-up of 30 months (1.5-152), OS and EFS at 5 years was 64.5±8.1% and 48.5±8.7% for patients with localized disease; and 16.2±7.9% and 14.4±7.3% for patients with initial metastatic disease, respectively. In patients with localized disease, conservative surgery was performed on 22 of 46 patients (43.5%), and there was no significant difference in survival rates among patients who had conservative vs radical surgery (p=0.65). Although tumor size (>12cm) was significant prognostic factor in univariate analysis; multivariate analysis identified elevated levels of alkaline phosphatase (p=0.033) and poor response to neoadjuvant chemotherapy (p<0.001) only as independent prognostic factors. Age, histological type, pathological fracture and primary tumor site did not significantly affect prognosis. Conclusion: Initial elevated presence of alkaline phosphatase in serum and poor histological response after neoadjuvant chemotherapy were significant factors for unfavorable prognosis. It is necessary to optimize staging and treatment intensification to improve survival rates, especially among patients with metastasis at initial presentation.

12 February 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
LVLiliana Vasquez
Liliana Vasquez
RDRosdali Diaz
Rosdali Diaz
SCSharon Chavez
Sharon Chavez
FTFanny Tarrillo
Fanny Tarrillo
IMIvan Maza
Ivan Maza
NRNuria Rossell
Nuria Rossell

9 July 2016 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
LVLiliana Vasquez
Liliana Vasquez
MOMonica Oscanoa
Monica Oscanoa
MTMariela Tello
Mariela Tello
ETElena Tapia
Elena Tapia
IMIvan Maza
Ivan Maza
JGJenny Geronimo
Jenny Geronimo